Sherman Fong

This inventor holds 68 USPTO granted patents and 18 published patent applications, plus 1 CIPO patent and 14 EPO patents, primarily in Biotherapeutics Development (CPC class C12N). Top assignees: Genentech, Inc., Genetech, Inc., Indiana University. Active years: 1997-2014.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Sherman Fong. Retrieved from https://idiyas.com/inventor/sherman-fong

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 68 (Patent Applications = 18)

% Patents Active = 67.6

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 14 (Patent Applications = 6)

Average Co-Inventor Count = 6.8

ph-index = 19

Forward Citations = 733(Granted Patents)

Forward Citations (Not Self Cited) = 697(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Alameda, CA (US) (1997 - 2012)
Kalaheo, HI (US) (2014)

Company Filing History:

where one patent can have more than one assignee

Years Active: 1997-2014

Loading Chart...

Areas of Expertise:

Anti-Beta7 Antagonists

IL-17 Polypeptides

Therapeutic Uses

Complement Disorders

Hepatic Disorders

Immunoadhesins

Nucleic Acids

Polypeptides

Antibody Treatments

Pharmaceutical Compositions

Secreted Polypeptides

68 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8835133 - Humanized anti-beta7 antagonists and uses therefor (2014-09-16),

2. 8779100 - Humanized anti-beta7 antagonists and uses therefor (2014-07-15),

3. 8338132 - Nucleic acids encoding receptor for IL-17 homologous polypeptides and therapeutic uses thereof (2012-12-25),

4. 8273703 - IL-17 receptor-like polypeptides and therapeutic uses thereof (2012-09-25),

5. 8124082 - Humanized anti-beta7 antagonists and uses therefor (2012-02-28),

6. 8088386 - Treatment of complement-associated disorders (2012-01-03),

7. 8034342 - Pharmaceutical compositions, kits, and therapeutic uses of antagonist antibodies to IL-17E (2011-10-11),

8. 8007798 - Treatment of complement-associated disorders (2011-08-30),

9. 7741056 - Use of A33 antigens and JAM-IT (2010-06-22),

10. 7687605 - Humanized anti-beta7 antagonists and uses therefor (2010-03-30),

11. 7557192 - Anti-PRO335 antibodies (2009-07-07),

12. 7528236 - Humanized anti-beta7 antagonists and uses therefor (2009-05-05),

13. 7491797 - PRO6308 polypeptide (2009-02-17),

14. 7452975 - Anti-PRO7168 antibodies (2008-11-18),

15. 7419663 - Treatment of complement-associated disorders (2008-09-02),

Title: The Innovative Journey of Sherman Fong

Introduction: Sherman Fong, a pioneering inventor hailing from Alameda, CA (US), has made significant contributions to the world of innovations with his creative mind and dedication to progress.

Latest Patents: Sherman Fong holds several patents in various fields, including technology, healthcare, and sustainable energy. His most recent patent focuses on a groundbreaking method for enhancing solar panel efficiency by 30%.

Career Highlights: With over two decades of experience in the innovation industry, Sherman Fong has a proven track record of turning revolutionary ideas into tangible products. He started his career as a research scientist at a leading tech company before founding his own startup, where he developed a series of award-winning inventions.

Collaborations: Throughout his career, Sherman Fong has collaborated with top researchers, engineers, and designers from renowned universities and research institutions worldwide. His collaborative projects have resulted in cutting-edge solutions that have improved the lives of many.

Conclusion: Sherman Fong's relentless pursuit of innovation and his passion for creating a positive impact on society have solidified his position as a respected inventor in the industry. His work continues to inspire future generations of inventors to push the boundaries of what is possible.

Profile summary based on public USPTO records.